540359 — Parmax Pharma Share Price
0.000.00%
Last trade - 00:00- IN₹1.68bn
- IN₹1.74bn
- IN₹110.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.13 | ||
| EV to EBITDA | 8,908.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.23% | ||
| Return on Equity | -134.65% | ||
| Operating Margin | -5.77% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | n/a | n/a | 154.24 | 110.53 | n/a | n/a | -28.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Parmax Pharma Ltd is an India-based company, which is engaged in active pharmaceutical ingredients (API) and contract manufacturing operations (CMO) business. It uses quality by design techniques to produce complex molecules enabling customers to create formulations. The Company’s manufacturing units run in accordance with current good manufacturing practices (cGMP). Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Ormeloxifene Hydrochloride I.P., Milnacipram HCl, Calciumpoly Carbophil usp, Levosulpride, Paliperidone, Edaravone, Lacosamide, Iloperidone, Prasugrel HCl, 2-Acetyl Thiophene, Morpholine Hydrochloride, Camphor Sulfonyl Chloride, ISB-I (2-Chlorobenzaldehyde-5-Sulfonic acid disodium salt), Benzaldehyde-2, 5-Di-Sulfonic acid disodium salt, 2-picolinoxylidide, 4-Octyl amino pyridine (4-OAP), Sitagliptin phosphate Monohydrate API, Solifenacin Succinate API, Vilazodone Hydrochloride API, and Azelnidipine API.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 2nd, 1994
- Public Since
- March 16th, 2017
- No. of Employees
- 88
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 37,413,000
- Address
- Plot No. 20, Survey No. 52, RAJKOT, 360311
- Web
- https://www.parmaxpharma.com/
- Phone
- +91 2827270534
- Auditors
- BA Shah S R Mehta & Co
Upcoming Events for 540359
Q1 2026 Parmax Pharma Ltd Earnings Release
Parmax Pharma Ltd Annual Shareholders Meeting
Similar to 540359
Aayush Wellness
Bombay Stock Exchange
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
FAQ
What is the Parmax Pharma share price?
As of Today at 22:34 UTC, shares in Parmax Pharma are trading at IN₹45.28. This share price information is delayed by 15 minutes.
How has the Parmax Pharma share price performed this year?
Shares in Parmax Pharma last closed at IN₹45.28 and the price had moved by +51.95% over the past 365 days. In terms of relative price strength the Parmax Pharma share price has outperformed the S&P BSE 100 Index by +43.14% over the past year.
What are the analyst and broker recommendations for Parmax Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Parmax Pharma dividend yield?
Parmax Pharma does not currently pay a dividend.
Does Parmax Pharma pay a dividend?
Parmax Pharma does not currently pay a dividend.
When does Parmax Pharma next pay dividends?
Parmax Pharma does not currently pay a dividend.
How do I buy Parmax Pharma shares?
To buy shares in Parmax Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Parmax Pharma?
As of the previous close price of IN₹45.28, shares in Parmax Pharma had a market capitalisation of IN₹1.68bn.
Where are Parmax Pharma shares listed?
Here are the trading details for Parmax Pharma:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 540359
What kind of share is Parmax Pharma?
Based on an overall assessment of its quality, value and momentum Parmax Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Parmax Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Parmax Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Parmax Pharma. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +1.96%.
As of the last closing price of IN₹45.28, shares in Parmax Pharma were trading +8.42% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Parmax Pharma PE Ratio?
The Parmax Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹45.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Parmax Pharma?
We do not have data on Parmax Pharma's directors